The newly appointed scientific and medical experts will guide product development, research, regulatory planning, and commercialization.
YourBio Health, the company behind TAP capillary blood collection technology, has launched a scientific and medical advisory board.
The newly formed board includes experts from across pediatrics, maternal-fetal medicine, genomics, and digital health, united by the belief that the future of diagnostics depends on moving beyond centralized collection by developing a painless blood collection device that can be used by anyone in any setting.
“Twenty percent of Americans avoid needles for a variety of reasons—and that avoidance leads to missed diagnoses for patients, increased costs for everyone, and broken trust between doctors and patients,” says Michael Mina, MD, PhD, chief scientific officer at YourBio Health, in a release. “TAP solves for pain, for access, for accuracy, and it does it across every setting: home, clinic, or hospital.”
The YourBio Health scientific and medical advisory board aims to accelerate the company’s momentum by providing expertise across product development, regulatory strategy, clinical research, and go-to-market execution.
The board is organized into two units—a scientific advisory board led by Mina and a medical advisory board led by Chet Robson, DO, MHCDS, FAAFP, chief medical officer at YourBio Health. Together, these groups will serve as the company’s external expert panel.
Inaugural advisory board members also include:
- Zev Williams, MD, PhD – Chief, Division of Reproductive Endocrinology and Infertility, Columbia University
- Andrea G. Edlow, MD, MSc – Vice Chair of Research, MGH; Associate Professor, Harvard Medical School
- Jennifer Hyde, MD – Westwood-Mansfield Pediatrics; Past Chair, PPOC Board
- Bernard Esquivel, MD, PhD – CEO, GenXys; VP Clinical Innovation, ixlayer
- Matt Ferber, PhD – Director of Clinical Genomics, Helix
- Jami Elliott, PhD – Strategic Initiatives, Office of the CMO, Thermo Fisher Scientific
YourBio Health is expanding the use of its TAP device beyond pediatric networks, pharmaceutical R&D, home care, and clinical trials, while also working to secure broader reimbursement and adoption of capillary blood collection.
Photo caption: TAP
Photo credit: YourBio Health/file photo
